Stock listing
B3:ABTT34 Abbott Laboratories Ações
Brazilian listing (B3) of Abbott Laboratories · home listing NYSE:ABT
Follow Abbott Laboratories into a list and get an email when it puts out news.
Share price · BMFBOVESPA:ABTT34
51.40 BRL +0.79 (+1.6%)
Close on Nov 19, 2026
- Day range
- 51.40 – 51.40 BRLNov 19, 2026
- Volume
- 105 sharesNov 19, 2026
- Market cap
- 1.07T BRLAt the close on Nov 19, 2026 · price × 20.76B shares outstanding
- 52-week range
- 33.50 – 58.85 BRLLowest and highest trades, Nov 21, 2025 – Nov 19, 2026
- Traded on an average day
- 17,694 BRLMedian day 109 shares · 2 days with no trades · last 3 months, Aug 19, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:ABT · Home | $103.00 USD | -1.48 (-1.4%) | 7,292,834 | $104.32 | $105.50 | $102.80 | $104.48 | Close on Nov 20, 2026 |
| Xetra:ABL | €94.94 EUR | -0.62 (-0.6%) | 801 | €95.02 | €95.90 | €94.48 | €95.56 | Close on Nov 20, 2026 |
| BMV:ABT | $1,984.87 MXN | -5.13 (-0.3%) | 26 | $1,975.00 | $1,984.87 | $1,975.00 | $1,990.00 | Close on Nov 19, 2026 |
| B3:ABTT34 | 51.40 BRL | +0.79 (+1.6%) | 105 | 51.40 | 51.40 | 51.40 | 50.61 | Close on Nov 19, 2026 |
| Cboe Canada:ABT | $17.93 CAD | -0.25 (-1.4%) | 800 | $18.06 | $18.06 | $17.93 | $18.18 | Close on Nov 20, 2026 |
| Stuttgart:ABL | €101.15 EUR | -1.80 (-1.7%) | 567 | €102.45 | €104.15 | €100.35 | €102.95 | Close on Nov 5, 2026 |
| Frankfurt:ABL | €95.66 EUR | +0.32 (+0.3%) | 113 | €94.80 | €95.94 | €94.80 | €95.34 | Close on Nov 20, 2026 |
| LSE:0Q15 | $104.06 USD | +0.29 (+0.3%) | 19,611 | $103.72 | $105.59 | $103.16 | $103.77 | Close on Nov 20, 2026 |
| Munich:ABL | €94.91 EUR | -0.09 (-0.1%) | — | €94.91 | €94.91 | €94.91 | €95.00 | Close on Nov 20, 2026 |
| Hamburg:ABL | €94.84 EUR | -0.26 (-0.3%) | — | €94.58 | €95.08 | €94.54 | €95.10 | Close on Nov 20, 2026 |
| Dusseldorf:ABL | €94.36 EUR | -0.04 (0.0%) | — | €94.46 | €95.24 | €94.36 | €94.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 6, 2026 · BMFBOVESPA:ABTT34 · BRL, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 50.55 | -1.90 | -3.6% | 52.22 | 52.22 | 50.55 | 13 | |
| 52.45 | 0.00 | 0.0% | 52.45 | 52.45 | 52.45 | 170 | |
| 52.45 | +2.53 | +5.1% | 50.66 | 52.56 | 50.66 | 1,822 | |
| 49.92 | +1.91 | +4.0% | 49.60 | 50.08 | 49.60 | 82 | |
| 48.01 | +1.36 | +2.9% | 48.00 | 48.01 | 48.00 | 55 | |
| 46.65 | -2.54 | -5.2% | 48.19 | 48.19 | 46.65 | 109 | |
| 49.19 | +3.10 | +6.7% | 45.20 | 49.19 | 45.20 | 555 | |
| 46.09 | -1.05 | -2.2% | 46.60 | 46.60 | 46.09 | 86 | |
| 47.14 | +4.10 | +9.5% | 45.14 | 47.57 | 45.14 | 2,497 | |
| 43.04 | -0.08 | -0.2% | 43.56 | 43.56 | 42.88 | 24 | |
| 43.12 | +1.28 | +3.1% | 42.68 | 43.12 | 42.68 | 247 | |
| 41.84 | -1.10 | -2.6% | 42.00 | 42.00 | 41.08 | 94 | |
| 42.94 | -0.70 | -1.6% | 44.07 | 44.07 | 42.64 | 358 | |
| 43.64 | -0.76 | -1.7% | 43.76 | 43.88 | 43.64 | 758 | |
| 44.40 | +0.12 | +0.3% | 44.70 | 44.70 | 44.20 | 173 | |
| 44.28 | +1.43 | +3.3% | 43.10 | 44.32 | 43.10 | 4,946 | |
| 42.85 | -0.33 | -0.8% | 42.31 | 43.17 | 40.40 | 56 | |
| 43.18 | +1.58 | +3.8% | 42.30 | 43.18 | 42.30 | 4 | |
| 41.60 | 0.00 | 0.0% | 41.60 | 41.60 | 41.60 | 0 | |
| 41.60 | +0.30 | +0.7% | 41.33 | 41.60 | 41.30 | 105 | |
| 41.30 | -0.10 | -0.2% | 41.82 | 41.82 | 40.60 | 69 | |
| 41.40 | +0.64 | +1.6% | 40.70 | 41.40 | 40.70 | 237 | |
| 40.76 | -1.11 | -2.7% | 41.66 | 41.66 | 40.76 | 588 | |
| 41.87 | -0.58 | -1.4% | 42.45 | 42.45 | 40.77 | 678 | |
| 42.45 | +0.12 | +0.3% | 42.18 | 42.45 | 42.18 | 57 | |
| 42.33 | -0.36 | -0.8% | 42.65 | 42.65 | 42.27 | 89 | |
| 42.69 | -1.15 | -2.6% | 42.69 | 42.69 | 42.69 | 19 | |
| 43.84 | -0.14 | -0.3% | 43.50 | 43.92 | 43.40 | 14 | |
| 43.98 | +0.08 | +0.2% | 44.34 | 44.34 | 43.98 | 18 | |
| 43.90 | +0.08 | +0.2% | 43.95 | 44.07 | 43.45 | 125 | |
| 43.82 | -0.62 | -1.4% | 44.32 | 44.32 | 43.82 | 36 | |
| 44.44 | -5.57 | -11.1% | 44.98 | 44.98 | 44.28 | 409 | |
| 50.01 | +6.09 | +13.9% | 44.36 | 50.01 | 44.32 | 218 | |
| 43.92 | -0.05 | -0.1% | 43.89 | 43.92 | 43.76 | 283 | |
| 43.97 | 0.00 | 0.0% | 44.41 | 44.41 | 43.60 | 49 | |
| 43.97 | -6.03 | -12.1% | 43.70 | 44.13 | 43.24 | 1,020 | |
| 50.00 | +6.20 | +14.2% | 43.80 | 50.00 | 43.79 | 32 | |
| 43.80 | -0.40 | -0.9% | 43.90 | 43.90 | 43.80 | 63 | |
| 44.20 | +0.49 | +1.1% | 44.28 | 44.44 | 44.20 | 81 | |
| 43.71 | -0.33 | -0.7% | 44.04 | 44.04 | 43.27 | 318 | |
| 44.04 | -0.99 | -2.2% | 44.50 | 44.50 | 44.04 | 70 | |
| 45.03 | -0.07 | -0.2% | 45.56 | 45.56 | 45.03 | 7 | |
| 45.10 | -1.25 | -2.7% | 46.35 | 46.35 | 44.90 | 328 | |
| 46.35 | 0.00 | 0.0% | 46.35 | 46.35 | 46.35 | 0 | |
| 46.35 | +0.01 | 0.0% | 46.51 | 46.51 | 46.35 | 11 | |
| 46.34 | -0.81 | -1.7% | 46.85 | 46.85 | 46.34 | 192 | |
| 47.15 | +0.25 | +0.5% | 47.35 | 47.59 | 47.05 | 599 | |
| 46.90 | -0.72 | -1.5% | 47.62 | 48.25 | 46.90 | 1,263 | |
| 47.62 | -1.28 | -2.6% | 47.45 | 47.80 | 47.45 | 304 | |
| 48.90 | +0.75 | +1.6% | 48.20 | 48.95 | 48.20 | 231 | |
| 48.15 | -1.25 | -2.5% | 48.10 | 48.15 | 48.10 | 78 | |
| 49.40 | -0.45 | -0.9% | 50.35 | 50.35 | 49.40 | 1,170 | |
| 49.85 | -0.20 | -0.4% | 49.60 | 49.90 | 49.52 | 20 | |
| 50.05 | +0.30 | +0.6% | 50.05 | 50.05 | 50.05 | 20 | |
| 49.75 | +0.40 | +0.8% | 49.00 | 49.95 | 49.00 | 216 | |
| 49.35 | +0.10 | +0.2% | 49.75 | 49.75 | 49.35 | 593 | |
| 49.25 | +0.20 | +0.4% | 49.50 | 49.54 | 49.04 | 197 |
Splits
1 split · BMFBOVESPA:ABTT34 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 3-for-1 | Split |
- Ticker
- B3:ABTT34
- Asset type
- Stock
- Exchange
- B3
- Currency
- BRL
What changed lately
Latest news release · Nov 19, 2026
Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis
Latest earnings call · Oct 21, 2026
Abbott Laboratories (NYSE:ABT) Q3 2026 Earnings Call
Replay and transcript
Latest news
Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
Nov 2, 2026
Closed 49.92 (+4.0%) on Nov 3, 2026
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
Nov 1, 2026
Closed 49.92 (+4.0%) on Nov 3, 2026
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
Oct 29, 2026
Closed 46.65 (-5.2%) on Oct 29, 2026
Abbott Laboratories receives FDA approval for first and only device in the U.S. to treat leaks after heart valve replacement without additional surgery
Oct 28, 2026
Closed 49.19 (+6.7%) on Oct 28, 2026
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Oct 26, 2026
Closed 47.14 (+9.5%) on Oct 26, 2026
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Oct 23, 2026
Closed 43.04 (-0.2%) on Oct 23, 2026
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Oct 21, 2026
Closed 41.84 (-2.6%) on Oct 21, 2026
Abbott Laboratories on 6ix
- News releases
- 83 in the last 12 months · 108 in all · newest Nov 19, 2026 · oldest 2025
- Calls
- 32 calls with a replay · 32 with a transcript · latest Oct 21, 2026
- Decks
- 34 decks · latest Nov 20, 2025
Where Abbott Laboratories is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:ABT · Home listing | NYSE | United States | USD |
| gettex:ABL | gettex | Germany | EUR |
| BCBA:ABT | BCBA | Argentina | ARS |
| Xetra:ABL | Xetra | Germany | EUR |
| TSX:ABT | TSX | Canada | CAD |
| Tradegate:ABL | Tradegate | Germany | EUR |
| BCBA:ABTD | BCBA | Argentina | USD |
| BMV:ABT | BMV | Mexico | MXN |
| LS Exchange:850103 | LS Exchange | Germany | EUR |
| B3:ABTT34 · This page | B3 | Brazil | BRL |
| Cboe Canada:ABT | Cboe Canada | Canada | CAD |
| Stuttgart:ABL | Stuttgart | Germany | EUR |
| BCBA:ABTC | BCBA | Argentina | USD |
| Frankfurt:ABL | Frankfurt | Germany | EUR |
| LSE:0Q15 | LSE | United Kingdom | USD |
| Milan:1ABT | Milan | Italy | EUR |
| Lang & Schwarz:850103 | Lang & Schwarz | Germany | EUR |
| SIX Swiss:ABT | SIX Swiss | Switzerland | CHF |
| BOATS:ABT | BOATS | United States | USD |
| VIE:ABT | Vienna | Austria | EUR |
| BCS:ABTCL | BCS | Chile | CLP |
| BCS:ABT | BCS | Chile | USD |
| Turquoise:ABTN | Turquoise | United Kingdom | USD |
| Munich:ABL | Munich | Germany | EUR |
| Aquis:ABLD | Aquis | United Kingdom | EUR |
| Hamburg:ABL | Hamburg | Germany | EUR |
| Hanover:ABL | Hanover | Germany | EUR |
| BSESOF:ABL | BSESOF | Bulgaria | EUR |
| BX Swiss:ABL | BX Swiss | Switzerland | CHF |
| BCBA:ABTB | BCBA | Argentina | ARS |
| Dusseldorf:ABL | Dusseldorf | Germany | EUR |
| BIVA:ABT | BIVA | Mexico | MXN |
| BCBA:ABTDB | BCBA | Argentina | USD |
| BVL:ABTUS | BVL | Peru | PEN |
| BCBA:ABTCB | BCBA | Argentina | USD |
| Aquis:ABLD | Aquis | United Kingdom | EUR |
| Frankfurt:ABL0 | Frankfurt | Germany | EUR |
| BCBA:ABT.CI | BCBA | Argentina | ARS |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $205.3B USD
- P/E
- 38.0×
- EV/sales
- 4.3×
- EV/EBITDA
- 25.0×
- Price/book
- 3.5×
- Gross margin
- 56.9%
- Operating margin
- 13.8%
- Net margin
- 9.8%
- Debt to equity
- 0.6×
- Beta vs S&P 500
- 0.11
Forecasts
18 strong buy · 5 buy · 5 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 118.91 USD · Analysts' mean
- EPS, year to Dec 2026
- 5.52 · 27 analysts
- Revenue, year to Dec 2026
- 49.95B · 25 analysts
Team and board
| Officer | Role |
|---|---|
| Rahul Singh | AVP |
Events
Calls
| Call | When | Status |
|---|---|---|
| Abbott Laboratories (NYSE:ABT) Q3 2026 Earnings Call | Wed, Oct 21, 2026 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q2 2026 Earnings Call | Thu, Jul 16, 2026 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q1 2026 Earnings Call | Thu, Apr 16, 2026 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call | Thu, Jan 22, 2026 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call | Wed, Oct 15, 2025 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q2 2025 Earnings Call | Thu, Jul 17, 2025 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Call | Wed, Apr 16, 2025 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q4 2024 Earnings Call | Wed, Jan 22, 2025 · 9:30 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q3 2024 Earnings Call | Wed, Oct 16, 2024 · 9:00 AM ET | Replay |
| Abbott Laboratories (NYSE:ABT) Q2 2024 Earnings Call | Thu, Jul 18, 2024 · 9:00 AM ET | Replay |
All 32 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 21, 2026 · Before open | −1.9% |
| Q2 2026 | Jul 16, 2026 · Before open | +10.7% |
| Q1 2026 | Apr 16, 2026 · Before open | −6.0% |
| Q4 2025 | Jan 22, 2026 · Before open | −10.0% |
| Q3 2025 | Oct 15, 2025 · Before open | −2.9% |
| Q2 2025 | Jul 17, 2025 · Before open | −8.5% |
| Q1 2025 | Apr 16, 2025 · Before open | +2.8% |
| Q4 2024 | Jan 22, 2025 · Before open | +0.8% |
| Q3 2024 | Oct 16, 2024 · Before open | +1.5% |
| Q2 2024 | Jul 18, 2024 · Before open | −4.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 17, 2024 · Before open | −3.0% |
| Q4 2023 | Jan 24, 2024 · Before open | −2.8% |
| Q3 2023 | Oct 18, 2023 · Before open | +3.7% |
| Q2 2023 | Jul 20, 2023 · Before open | +4.2% |
| Q1 2023 | Apr 19, 2023 · Before open | +7.8% |
| Q4 2022 | Jan 25, 2023 · Before open | −1.4% |
| Q3 2022 | Oct 19, 2022 · Before open | −6.5% |
| Q2 2022 | Jul 20, 2022 · Before open | −1.6% |
| Q1 2022 | Apr 20, 2022 · Before open | +2.2% |
| Q4 2021 | Jan 26, 2022 · Before open | −2.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (November 2025) | Merger or acquisition | 13 slides | Nov 20, 2025 |
| Technical Presentation (October 2025) | Technical | 16 slides | Oct 26, 2025 |
| Investor Presentation (October 2024) | Investor deck | 41 slides | October 2024 |
| Conference Presentation (October 2024) | Conference | 24 slides | October 2024 |
| Technical Presentation (November 2023) | Technical | 8 slides | November 2023 |
| Fact Sheet (October 2023) | Fact sheet | 1 slide | Oct 11, 2023 |
| Investor Presentation (May 2022) | Investor deck | 30 slides | May 2022 |
| Technical Presentation (April 2022) | Technical | 24 slides | April 2022 |
| a:care Congress (November 2021) | Conference | 40 slides | November 2021 |
| Technical Presentation (October 2021) | Technical | 21 slides | October 2021 |
All 34 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.3B | 42.0B | 40.1B | 43.7B | 43.1B | 34.6B | 31.9B | 30.6B | 27.4B | 20.9B |
| Cost of revenue | 19.3B | 18.7B | 18.0B | 19.1B | 18.5B | 15.0B | 13.2B | 12.7B | 12.4B | 9.09B |
| Gross profit | 25.0B | 23.2B | 22.1B | 24.5B | 24.5B | 19.6B | 18.7B | 17.9B | 15.0B | 11.8B |
| Research and development | 2.94B | 2.84B | 2.74B | 2.89B | 2.74B | 2.42B | 2.44B | 2.30B | 2.26B | 1.45B |
| Selling, general and administrative | 12.3B | 11.7B | 10.9B | 11.2B | 11.3B | 9.70B | 9.77B | 9.74B | 9.18B | 6.74B |
| Operating income | 8.05B | 6.83B | 6.48B | 8.36B | 8.43B | 5.36B | 4.53B | 3.65B | 1.56B | 3.03B |
| Depreciation and amortization | 1.43B | 1.34B | 1.28B | 1.25B | 1.49B | 1.20B | 1.08B | 1.10B | 1.05B | 803.0M |
| EBITDA | 9.49B | 8.16B | 7.75B | 9.62B | 9.92B | 6.55B | 5.61B | 4.75B | 2.61B | 3.83B |
| Interest expense | 493.0M | 559.0M | 637.0M | 558.0M | 533.0M | 546.0M | 670.0M | 826.0M | 904.0M | 431.0M |
| Income before tax | 8.47B | 7.01B | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B |
| Income tax | 1.94B | -6.39B | 941.0M | 1.37B | 1.14B | 497.0M | 390.0M | 539.0M | 1.88B | 350.0M |
| Net income | 6.52B | 13.4B | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.0M | 1.40B |
| Earnings per share, basic | 3.73 | 7.67 | 3.28 | 3.94 | 3.97 | 2.52 | 2.07 | 1.34 | 0.27 | 0.94 |
| Earnings per share, diluted | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 | 1.33 | 0.27 | 0.94 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.52B | 7.62B | 6.90B | 9.88B | 9.80B | 6.84B | 3.86B | 3.84B | 9.41B | 18.6B |
| Short-term investments | 417.0M | 351.0M | 383.0M | 288.0M | 450.0M | 310.0M | 280.0M | 242.0M | 203.0M | 155.0M |
| Receivables | 7.93B | 6.92B | 6.57B | 6.22B | 6.49B | 6.41B | 5.42B | 5.18B | 5.25B | 3.25B |
| Inventory | 6.49B | 6.19B | 6.57B | 6.17B | 5.16B | 5.01B | 4.32B | 3.80B | 3.60B | 2.43B |
| Current assets | 26.0B | 23.7B | 22.7B | 25.2B | 24.2B | 20.4B | 15.7B | 14.6B | 20.1B | 26.8B |
| Property, plant and equipment | 11.8B | 10.7B | 10.2B | 9.16B | 8.96B | 9.03B | 8.04B | 7.56B | 7.61B | 5.71B |
| Goodwill | 24.0B | 23.1B | 23.7B | 22.8B | 23.2B | 23.7B | 23.2B | 23.3B | 24.0B | 7.68B |
| Total assets | 86.7B | 81.4B | 73.2B | 74.4B | 75.2B | 72.5B | 67.9B | 67.2B | 76.3B | 52.7B |
| Current liabilities | 16.5B | 14.2B | 13.8B | 15.5B | 13.1B | 11.9B | 10.9B | 9.01B | 8.91B | 6.66B |
| Long-term debt | 9.90B | 12.6B | 13.6B | 14.5B | 17.3B | 18.5B | 16.7B | 19.4B | 27.2B | 20.7B |
| Total debt | 12.9B | 14.1B | 14.7B | 16.8B | 18.1B | 18.7B | 18.1B | 19.6B | 27.9B | 22.0B |
| Shareholders' equity | 52.1B | 47.7B | 38.6B | 36.7B | 35.8B | 32.8B | 31.1B | 30.5B | 30.9B | 20.5B |
| Shares outstanding | 1.73B | 1.74B | 1.74B | 1.73B | 1.74B | 1.74B | 1.76B | 1.77B | 1.76B | 1.76B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 9.57B | 8.56B | 7.26B | 9.58B | 10.5B | 7.90B | 6.14B | 6.30B | 5.57B | 3.20B |
| Capital spending | -2.17B | -2.21B | -2.20B | -1.78B | -1.89B | -2.18B | -1.64B | -1.39B | -1.14B | -1.12B |
| Free cash flow | 7.39B | 6.35B | 5.06B | 7.80B | 8.65B | 5.72B | 4.50B | 4.91B | 4.43B | 2.08B |
| Cash from investing | -2.42B | -2.34B | -3.13B | -1.74B | -2.01B | -2.21B | -1.81B | -1.36B | -9.62B | -248.0M |
| Cash from financing | -6.31B | -5.40B | -7.09B | -7.64B | -5.49B | -2.78B | -4.29B | -10.4B | -5.28B | 11.1B |
| Dividends paid | -4.12B | -3.84B | -3.56B | -3.31B | -3.20B | -2.56B | -2.27B | -1.97B | -1.85B | -1.54B |
| Share buybacks | -893.0M | -1.29B | -1.23B | -3.79B | -2.30B | -403.0M | -718.0M | -238.0M | -117.0M | -522.0M |
| Change in cash | 906.0M | 720.0M | -2.99B | 83.0M | 2.96B | 2.98B | 16.0M | -5.56B | -9.21B | 13.6B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 13, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 5, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 21, 2026 | Current report | SEC |
| 8-K · Current report | Oct 21, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 16, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 11-K · Annual report of an employee plan | Jun 18, 2026 | Annual report | SEC |
| SD · Specialized disclosure | May 27, 2026 | ESG report | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Apr 29, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 27, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Apr 24, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 17, 2026 | Current report | SEC |
| 8-K · Current report | Apr 16, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 25, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 23, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 23, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Mar 13, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 13, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 9, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 25, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Feb 23, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Feb 23, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Feb 23, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 20, 2026 | Current report | SEC |
| 10-K · Annual report | Feb 20, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 22, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 21, 2025 | Current report | SEC |
| 8-K · Current report | Nov 20, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Oct 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 15, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 17, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2025 | Insider trade | SEC |
| 11-K · Annual report of an employee plan | Jun 20, 2025 | Annual report | SEC |
| SD · Specialized disclosure | May 29, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 1, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Apr 30, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Apr 30, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 28, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Apr 16, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 14, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 14, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 14, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 7, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Mar 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 10-K · Annual report | Feb 21, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 29, 2025 | Other filings | SEC |
This page holds 200 of 1,002 filings. Open Filings
Cap table
Built by 6ix from Abbott Laboratories’ releases · as of Sep 30, 2026
- Common shares
- 1,731,941,601
- Fully diluted
- 1,731,941,601
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,731,941,601 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 30, 2026 | 1,731,941,601 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Edward M Liddy Other companies: AbbVie Inc. (Director · Dec 12, 2012 – Mar 31, 2022 · Past); American International Group, Inc. New (Chairman & CEO, Director · Sep 18, 2008 – Sep 18, 2008 · Past); Boeing Company (the) (Director · Aug 28, 2007 – Apr 1, 2020 · Past); Goldman Sachs Group, Inc. (the) (Director · Dec 15, 2006 – Dec 19, 2007 · Past); Allstate Corporation (the) (Chairman, Director · Feb 21, 2006 – Feb 22, 2008 · Past); 3M Company (Director · Dec 31, 2005 – May 1, 2020 · Past); Kroger Company (the) (Director · Dec 31, 2005 – Dec 31, 2005 · Past) | Director · Jun 11, 2010 – Apr 24, 2020 · Past |
| Jack M Greenberg Other companies: IQVIA Holdings, Inc. (Director · May 8, 2013 – Apr 26, 2018 · Past); Western Union Company (the) (Director · Sep 29, 2009 – Feb 20, 2015 · Past); InnerWorkings Inc (Director · Aug 15, 2006 – Oct 1, 2020 · Past); Allstate Corporation (the) (Director · Feb 23, 2006 – Mar 5, 2015 · Past); First Data Corporation (Director · Feb 8, 2006 – Sep 1, 2006 · Past); Hasbro, Inc. (Director · Dec 30, 2005 – Mar 31, 2015 · Past); ManpowerGroup (Director · Dec 30, 2005 – Jan 1, 2014 · Past) | Director · Apr 28, 2006 – Apr 28, 2006 · Past |
| Glenn F Tilton Other companies: Phillips 66 (Director · Since at least May 1, 2012); AbbVie Inc. (Director · Dec 12, 2012 – May 9, 2025 · Past); Corning Incorporated (Director · Nov 30, 2010 – Feb 1, 2012 · Past); United Airlines Holdings, Inc. (Director · Feb 1, 2006 – Jun 12, 2013 · Past); Txu Corp (Director · Jan 9, 2006 – Jan 9, 2007 · Past); Lincoln National Corporation (Director · Dec 30, 2005 – Mar 31, 2007 · Past) | Director · Apr 27, 2007 – Apr 29, 2022 · Past |
| Kevin T Conroy Other companies: American Exceptionalism Acquisition Corp. A (Director · Since at least Sep 25, 2025); Align Technology, Inc. (Director · Since at least Dec 5, 2023); EXACT Sciences Corporation (President and CEO, Director · Since at least Mar 18, 2009); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Mar 6, 2023 · Past); ARYA Sciences Acquisition Corp (Director · Oct 5, 2018 – Jul 1, 2020 · Past); Epizyme Inc (Director · Feb 6, 2017 – Aug 12, 2022 · Past) | Director · Since at least Apr 24, 2026 |
| Roxanne Austin Other companies: Freshworks Inc. (Director · Since at least Sep 21, 2021); Verizon Communications Inc. (Director · Since at least Oct 2, 2020); CrowdStrike Holdings, Inc. (President, Austin Investment Advisors · Since at least Jun 11, 2019); AbbVie Inc. (President · Since at least Dec 12, 2012); Teledyne Technologies Incorporated (Director · Jan 29, 2006 – Jun 5, 2020 · Past); Target Corporation (Director · Jan 11, 2006 – Jun 2, 2020 · Past) | Director · Apr 28, 2006 – Apr 23, 2021 · Past |
| W James Farrell Other companies: 3M Company (Director · Aug 14, 2006 – May 13, 2014 · Past); Allstate Corporation (the) (Director · Jun 1, 2006 – Dec 7, 2012 · Past); United Airlines Holdings, Inc. (Director · Feb 1, 2006 – Jun 9, 2012 · Past); Illinois Tool Works Inc. (Chairman, Director · Jan 5, 2006 – Apr 21, 2006 · Past); Mondelez International, Inc. (Director · Dec 31, 2005 – Apr 26, 2006 · Past) | Director · Jan 16, 2006 – Apr 29, 2016 · Past |
| William A Osborn Other companies: General Dynamics Corporation (Director · Dec 1, 2009 – Mar 8, 2021 · Past); Caterpillar, Inc. (Director · Jun 14, 2006 – Mar 1, 2021 · Past); Tribune Media Company (Director · May 3, 2006 – Dec 20, 2007 · Past); Northern Trust Corporation (Chairman of the Board, Director · Jan 20, 2006 – Dec 15, 2008 · Past) | Director · Jan 2, 2008 – Apr 29, 2022 · Past |
| William G Dempsey Other companies: Ashland Inc. (Director · Jul 20, 2016 – Dec 30, 2022 · Past); Hill-Rom Holdings Inc (Director · Mar 7, 2014 – Dec 13, 2021 · Past); Hospira Inc (Director · Aug 17, 2011 – Sep 3, 2015 · Past); Landauer Inc (Director · Oct 30, 2008 – Oct 19, 2017 · Past) | Executive Vice President · Dec 31, 2005 – Aug 7, 2007 · Past |
| Carlos Albán Other companies: Solventum Corporation (Director · Since at least Apr 1, 2024); SpringWorks Therapeutics Inc (Director · Since at least Jul 14, 2022); AbbVie Inc. (Vice Chairman · Dec 7, 2012 – Nov 16, 2020 · Past) | Senior Vice President · Oct 15, 2009 – Dec 1, 2012 · Past |
| John G Stratton Other companies: Frontier Communications Parent Inc (Exec. Chairman of the Board, Director · Since at least Apr 30, 2021); General Dynamics Corporation (Director · Since at least Feb 5, 2020); Verizon Communications Inc. (EVP&Pres - Global Operations · Oct 5, 2017 – May 31, 2018 · Past) | Director · Since at least Sep 30, 2017 |
All 74 people
| Person | Seat |
|---|---|
| Michael Dale Other companies: CVRx, Inc. (Chief Executive Officer and President · Since at least Apr 20, 2026); Axogen, Inc. (President, Chief Executive Officer and Board Director · Since at least Aug 9, 2024); Ats Medical Inc (Chief Executive Officer · Jan 10, 2006 – Aug 12, 2010 · Past) | SENIOR VICE PRESIDENT · Nov 11, 2019 – Feb 28, 2023 · Past |
| Michelle Kumbier Other companies: Ryerson Holding Corporation (Director · Since at least Apr 25, 2024); Teledyne Technologies Incorporated (Director · Since at least Oct 20, 2020); Tenneco Inc (Director · Aug 10, 2021 – Nov 17, 2022 · Past) | Director · Since at least Feb 23, 2021 |
| Nancy McKinstry Other companies: Automatic Data Processing, Inc. (Director · Since at least Nov 11, 2026); Mondelez International, Inc. (Director · Since at least May 21, 2025); Accenture plc (Director · Since at least May 15, 2019) | Director · Since at least Apr 26, 2019 |
| Samuel C Scott III Other companies: GCM Grosvenor Inc. (Director · Since at least Nov 17, 2020); Motorola Solutions, Inc. (Director · May 16, 2016 – May 14, 2018 · Past); The Bank of New York Mellon Corporation (Director · Apr 22, 2016 – Feb 11, 2022 · Past) | Director · Apr 29, 2016 – Apr 26, 2019 · Past |
| Thomas C. Freyman Other companies: AbbVie Inc. (Director · Since at least May 8, 2020); Hanger Inc (Director · Nov 14, 2017 – Oct 3, 2022 · Past); Tenneco Inc (Director · Jul 14, 2015 – Nov 17, 2022 · Past) | Executive Vice President · Feb 19, 2016 – Jul 29, 2016 · Past |
| Thomas F Chen Other companies: Stericycle Inc (Director · May 21, 2014 – Nov 4, 2024 · Past); Baxter International Inc. (Director · Jan 25, 2013 – May 3, 2022 · Past); Cyanotech Corporation (Director · Jun 6, 2011 – Aug 27, 2012 · Past) | Senior Vice President · Apr 24, 2006 – May 25, 2010 · Past |
| William D Smithburg Other companies: Niagen Bioscience, Inc. (Director · Jun 6, 2016 – Jun 6, 2016 · Past); Corning Incorporated (Director · Dec 30, 2005 – Mar 30, 2012 · Past); Northern Trust Corporation (Director · Dec 30, 2005 – Apr 20, 2010 · Past) | Director · Dec 31, 2005 – Nov 9, 2010 · Past |
| Andrea F. Wainer Other companies: Neogen Corporation (Director · Since at least May 13, 2025); Analog Devices, Inc. (Director · Since at least Jan 9, 2025) | RETIRED EVP · Jun 3, 2019 – Feb 28, 2025 · Past |
| Daniel J Starks Other companies: Urologix (Director · Aug 22, 2006 – Nov 11, 2008 · Past); St. Jude Medical Inc (Director · Feb 7, 2006 – Jan 4, 2017 · Past) | Director · Since at least Feb 16, 2017 |
| Darren W McDew Other companies: GE Aerospace (Director · Since at least Mar 30, 2023); Parsons Corporation (Director · Since at least Apr 20, 2021) | Director · Since at least Apr 23, 2021 |
| Heather L. Mason Other companies: Immatics N.V. (Non-Executive Director · Since at least Mar 18, 2026); Assertio Holdings, Inc. (Director · Since at least May 19, 2020) | Executive Vice President · May 1, 2008 – Jul 1, 2017 · Past |
| James V Mazzo Other companies: Aerie Pharmaceuticals Inc. (Director · Jun 11, 2014 – Jun 11, 2014 · Past); Microsemi Corporation (Director · Aug 7, 2012 – Feb 11, 2014 · Past) | Senior Vice President · Aug 26, 2010 – Feb 4, 2013 · Past |
| Lisa D Earnhardt Other companies: Nevro Corp (Director · May 21, 2018 – May 21, 2018 · Past); Intersect ENT Inc (Director · Oct 16, 2017 – Jul 24, 2019 · Past) | EVP AND GROUP PRESIDENT · Since at least Jun 10, 2019 |
| Michael Roman Other companies: Waystar Holding Corp. (Director · Since at least Jun 4, 2025); 3M Company (Chairman of the Board, Director · Feb 2, 2016 – Feb 3, 2025 · Past) | Director · Since at least Apr 23, 2021 |
| Rahul Singh Other companies: Dow Inc. (AVP · Since at least May 15, 2026); 3M Company (AVP · Since at least Apr 27, 2026) | AVP · Since at least May 5, 2026 |
| Robert J Alpern Other companies: AbbVie Inc. (Director · Since at least Dec 12, 2012); Tricida Inc (Director · Jun 27, 2018 – Nov 23, 2022 · Past) | Director · Since at least Oct 10, 2008 |
| Roy S Roberts Other companies: AbbVie Inc. (Director · Dec 12, 2012 – May 8, 2015 · Past); Burlington Northern Santa Fe Corp (Director · Dec 30, 2005 – Feb 12, 2010 · Past) | Director · Dec 31, 2005 – Jan 31, 2011 · Past |
| Charles Brynelsen Other companies: Envoy Medical, Inc. (Director · Since at least Sep 29, 2023) | SENIOR VICE PRESIDENT · Feb 16, 2018 – Feb 26, 2021 · Past |
| Edward L Michael Other companies: QuidelOrtho Corporation (Director · Since at least May 27, 2022) | Executive Vice President · Mar 1, 2007 – Feb 29, 2012 · Past |
| Holger A Liepmann Other companies: Verenium Corp (Director · Mar 31, 2013 – Oct 31, 2013 · Past) | Executive Vice President · Jan 31, 2006 – Dec 23, 2010 · Past |
| Jacob A Orville Other companies: EXACT Sciences Corporation (EVP, GM, Screening · Since at least Feb 16, 2021) | Senior Vice President · Since at least Mar 23, 2026 |
| Jeffrey R Binder Other companies: Biomet Inc (President & CEO, Director · Feb 26, 2007 – Feb 26, 2007 · Past) | Senior Vice President · Jan 15, 2006 – Feb 17, 2007 · Past |
| John A McCoy Other companies: Baxalta Inc (SVP and Controller · Jun 30, 2015 – Jun 3, 2016 · Past) | VICE PRESIDENT AND CONTROLLER · Since at least Sep 1, 2023 |
| Michael O'Grady Other companies: Northern Trust Corporation (Chairman and CEO, Director · Since at least Dec 3, 2025) | Director · Since at least Apr 25, 2025 |
| Michael T Rousseau Other companies: St. Jude Medical Inc (Director, President and CEO, Director · Feb 3, 2006 – Jan 4, 2017 · Past) | Pres., Cardiovas. & Neuromod. · Jan 4, 2017 – Jul 7, 2017 · Past |
| Murthy V Simhambhatla Other companies: Evolus, Inc. Common Stock (See Remarks, Director · Feb 7, 2018 – Feb 7, 2018 · Past) | Senior Vice President · Jan 1, 2013 – Feb 27, 2015 · Past |
| Richard A Gonzalez Other companies: AbbVie Inc. (Director · Dec 7, 2012 – Mar 31, 2025 · Past) | Executive Vice President · Nov 17, 2005 – Apr 6, 2012 · Past |
| Sally E Blount Other companies: Ulta Beauty, Inc. (Director · Dec 6, 2017 – Jun 2, 2021 · Past) | Director · Since at least Dec 9, 2011 |
| A David Forrest | Senior Vice President · Sep 17, 2010 – Sep 17, 2013 · Past |
| Alejandro D Wellisch | SENIOR VICE PRESIDENT · Oct 1, 2017 – Feb 28, 2023 · Past |
| Andrew H Lane | EXECUTIVE VICE PRESIDENT · Feb 16, 2018 – Nov 15, 2021 · Past |
| Charles D Foltz | Senior Vice President · Apr 1, 2013 – Apr 1, 2015 · Past |
| Christopher J Calamari | SENIOR VICE PRESIDENT · Jul 1, 2021 – Feb 28, 2023 · Past |
| Christopher J Scoggins | EXECUTIVE VICE PRESIDENT · Since at least Apr 1, 2019 |
| Claire Babineaux-Fontenot | Director · Since at least Apr 25, 2025 |
| Daniel Gesua Sive Salvadori | EVP AND GROUP PRESIDENT · Since at least Sep 26, 2014 |
| Deepak S Nath | Senior Vice President · Apr 1, 2015 – Apr 28, 2017 · Past |
| Elizabeth C Cushman | EVP, GC AND SECRETARY · Since at least Jun 27, 2025 |
| Eric Shroff | Senior Vice President · Since at least Mar 1, 2025 |
| Fernando Mateus | SENIOR VICE PRESIDENT · Dec 1, 2021 – Feb 28, 2023 · Past |
| Georges H DeVos | Senior Vice President · Jul 1, 2013 – Feb 27, 2015 · Past |
| Hubert L Allen | EXECUTIVE VICE PRESIDENT, GC · Feb 1, 2021 – Feb 28, 2025 · Past |
| Jaime Contreras | Senior Vice President · Sep 16, 2013 – Apr 21, 2020 · Past |
| Jared Watkin | SENIOR VICE PRESIDENT · Jun 15, 2015 – Feb 28, 2023 · Past |
| Jean-Yves Pavee | Senior Vice President · Jul 1, 2013 – Jul 1, 2016 · Past |
| John F Ginascol | EXECUTIVE VICE PRESIDENT · Jun 3, 2019 – Feb 28, 2023 · Past |
| John M Capek | EXECUTIVE VICE PRESIDENT · Feb 17, 2023 – Feb 28, 2023 · Past |
| Joseph J Manning | EXECUTIVE VICE PRESIDENT · Jan 16, 2017 – Feb 28, 2023 · Past |
| Julie L Tyler | SENIOR VICE PRESIDENT · Jul 1, 2021 – Feb 28, 2023 · Past |
| Louis H Morrone | EXECUTIVE VICE PRESIDENT · Since at least Jul 1, 2021 |
| Mary K Moreland | EXECUTIVE VICE PRESIDENT · Since at least Feb 16, 2021 |
| Michael J Pederson | SENIOR VICE PRESIDENT · Jul 21, 2017 – Feb 28, 2023 · Past |
| Michael J Warmuth | Executive Vice President · Dec 15, 2008 – Feb 28, 2017 · Past |
| Nita Ahuja | Director · Since at least Dec 12, 2025 |
| Patricia Paola Gonzalez | Director · Since at least Aug 30, 2021 |
| Paul K Magill | Senior Vice President · Nov 1, 2012 – Feb 15, 2013 · Past |
| Philip P Boudreau | EVP AND CFO · Since at least Aug 8, 2025 |
| Randel William Woodgrift | SENIOR VICE PRESIDENT · Apr 1, 2019 – Feb 28, 2023 · Past |
| Robert B Ford | CHAIRMAN AND CEO, Director · Since at least Jun 6, 2019 |
| Robert E Funck Jr | EXECUTIVE VICE PRESIDENT · Mar 1, 2013 – May 10, 2024 · Past |
| Roger Bird | SENIOR VICE PRESIDENT · Mar 1, 2015 – Apr 27, 2021 · Past |
| Sean Shrimpton | Senior Vice President · May 15, 2017 – Dec 31, 2018 · Past |
| Sharon J Bracken | Senior Vice President · Jul 10, 2017 – Mar 31, 2019 · Past |
| Stephen R Fussell | Executive Vice President · Jan 30, 2018 – Apr 23, 2019 · Past |
Log in to ask 6ix AI your own questions about Abbott Laboratories.